ME/CFS Research Foundation Logo

Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Syndrome (VERI-LONG)


Principal investigator:
Study start:
Completion (planned):
Last update:


Research types:
Clinical research
Research areas:
Cardiovascular dysfunction
Vericiguat, Placebo
Priv. Sector Partner:

Project description

Note: The completion date of this research project currently displayed in the MRR is 2024-12-31. While the exact completion date is not available however, the research project is expected to be completed by the end of 2024.

As part of the clinical trials within the National Clinical Study Group (NKSG), the objective of this study is to demonstrate improvement in physical function measured using the short form-36 health questionnaire (SF-36) in patients with post-COVID-19 syndrome (PCS) with or without fulfillment of ME/CFS criteria treated with Vericiguat compared with placebo. Vericiguat is a drug that bridges endothelial dysfunction to improve microvascular perfusion and tissue and organ blood flow.

This is a two-arm parallel-group, randomized, placebo-controlled, double-blind, single-centre clinical trial in participants with PCS and PCS/CFS. Patients participate for approx. 18 weeks. Participants will be stratified according to diagnosis (with vs. without ME/CFS) and sex, and randomly assigned 1:1 after a screening phase of up to 28 days to receive assigned intervention of either 10 weeks of treatment with Vericiguat (including titration phase) or placebo, followed by 30 days follow-up period. One group receives a tablet of Vericiguat once daily for 10 weeks with a dosage titration to tolerated dose of 2.5 mg for 2 weeks, 5 mg for 2 weeks, 10 mg for 6 weeks. The other group receives a matching placebo tablet once daily for 10 weeks with the same titration regimen to ensure blinding. The starting dose is 2.5 mg Vericiguat or matching placebo, once daily, and a controlled and blood pressure-tolerated titration regimen will be used to achieve the anticipated target dose of 10 mg Vericiguat or matching placebo. Every participant will undergo trial, cardiovascular safety, and monitoring assessments. During the screening visit, the study team i) records the patient's medical history, ii) checks the in- and exclusion criteria, iii) performs a medical check-up, iv) performs an echocardiogram, and v) measures the patient's vital parameters. In female participants, a pregnancy test is carried out 5 times during the study.

The results of this study will provide insights on whether Vericiguat can alleviate PCS-related symptoms such as fatigue, cognitive impairment, and impaired physical function (e.g., walking, stair climbing) and/or modulate paraclinical markers such as parameters of endothelial function. Moreover, the clinical trial will provide insights into the pathophysiological processes of PCS, which in turn can help to elucidate the disease etiology and to develop effective therapies.

(Description adapted from clinical trial website: see link above)

Patient cohort

Post-COVID Syndrome (PCS) according to WHO as well as post-infectious ME/CFS according to Canadian Consensus Criteria (CCC), including post-COVID ME/CFS. Comparisson of sham/placebo vs treated patients.

Patients enrolled: 104

Age group: 18 - 50 years (Adults)

Research areas (2)
Research types (1)
Research networks (1)
Working groups (1)
People (2)
Publications (1)
Organisations (1)